Ionis FY2025 total revenue $944M (+34% YoY); guides 2026 rev $800-825M, op loss $500-550M

IONIS PHARMACEUTICALS INC

2025-FY EPS reported -$2.38 revenue$203,330,000

FY2025 total revenue $944M (2024: $705M); Q4 revenue $203M.
TRYNGOLZA net sales $108M in first launch year; DAWNZERA $7M in first full quarter.
SPINRAZA royalties $212M, WAINUA royalties $49M; collaborative rev $508M incl $280M Ono upfront.
2026 guidance: revenue $800-825M, non-GAAP op loss $500-550M, cash ~$1.6B.
Olezarsen sNDA for sHTG submitted; zilganersen NDA for Alexander disease decision H2 2026.

item 2.02item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.